Sciele Pharma Inc. has signed an agreement with Novo Nordisk to market exclusively Prandin, an oral blood gluclose-lowering drug.

Sciele Pharma Inc. has signed an agreement with Novo Nordisk to market exclusively Prandin, an oral blood gluclose-lowering drug. The agreement allows Sciele to exclusively market Prandin and PrandiMet (a combination tablet of repaglinide and metformin) to U.S. doctors. Sciele also gained the right of first refusal on U.S. marketing rights for other Novo Nordisk products containing repaglinide, the active pharmaceutical ingredient in Prandin and PrandiMet. The U.S. Food & Drug Administration still must approve PrandiMet.

Sciele recently reported a profit of $13.8 million on $99.4 million in revenue in the third quarter.